NCT07143812 is a Phase 1 clinical trial of MSC11FCD in Glioblastoma (GBM), sponsored by CHA University.

Who is sponsoring NCT07143812?

NCT07143812 is sponsored by CHA University.

What drugs are being tested in NCT07143812?

Interventions in NCT07143812: MSC11FCD.

What condition does NCT07143812 study?

NCT07143812 studies Glioblastoma (GBM), Newly Diagnosed Glioblastoma Multiforme.

Is NCT07143812 still recruiting?

NCT07143812 is currently recruiting now. Last updated 22 January 2026.

Last reviewed 2026-01-22 · How we verify

NCT07143812

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study to Evaluate the Safety of a Stem Cell-Based Gene and Cell Therapy in Patients With Newly Diagnosed Glioblastoma

Recruiting now Phase 1 Last updated 22 January 2026

What this trial tests

Phase 1 trial testing MSC11FCD in Glioblastoma (GBM) in 10 participants. Currently enrolling.

Timeline

23 October 2025

Primary endpoint
31 December 2026

31 December 2026

Quick facts

Lead sponsor	CHA University
Phase	Phase 1
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	10
Start date	23 October 2025
Primary completion	31 December 2026
Estimated completion	31 December 2026
Sites	1 location across South Korea

Drugs / interventions tested

MSC11FCD — full drug profile →

Conditions studied

Glioblastoma (GBM) — all drugs for Glioblastoma (GBM) →
Newly Diagnosed Glioblastoma Multiforme — all drugs for Newly Diagnosed Glioblastoma Multiforme →

Sponsor

CHA University

Who can join

Adults 19 to 70, any sex, with Glioblastoma (GBM) or Newly Diagnosed Glioblastoma Multiforme. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a phase I clinical trial evaluating the safety, tolerability, and maximum tolerated dose of MSC11FCD, an investigational allogeneic bone marrow-derived mesenchymal stem cell therapy expressing a suicide gene, in patients with newly diagnosed glioblastoma. The investigational product is administered intratumorally following surgical resection. This study aims to explore whether MSC11FCD can provide a targeted, localized treatment option during the postsurgical period, potentially addressing residual tumor cells and reducing early recurrence.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Astrocytes in neuroinflammation and brain cancer.
Sun W, Chen P, Xu XY, Zhang JQ, et al · · 2026 · PMID 41910655 · DOI 10.1186/s43556-026-00439-y
Mesenchymal Stromal/Stem Cells (MSCs) in Cancer Therapy: Advanced Therapeutic Strategies Towards Future Clinical Translation.
Kucharczyk H, Tarnowski M, Tkacz M. · · 2025 · PMID 41471830 · DOI 10.3390/molecules30244808

Verify or expand the search:

Other trials of MSC11FCD

Trials testing the same drug.

NCT04657315 — Evaluation of Maximum Tolerated Dose, Safety and Efficiency of MSC11FCD Therapy to Recurrent Glioblastoma Patients · Phase 1, PHASE2 · completed

Other recruiting trials for Glioblastoma (GBM)

Currently open trials in the same condition.

NCT07409584 — Mental Health and Suicidality in Glioblastoma Patients in Germany · recruiting
NCT07511725 — Prophylactic Regimen With Intrathecal Thiotepa in SVZ-positive or Meningeal-risk Glioblastoma · Phase 2 · recruiting
NCT06717295 — The CCANED-CIPHER Study: Early Cancer Detection and Treatment Response Monitoring Using AI-Based Platelet and Immune Cel · recruiting
NCT06989086 — FearLess in NeuroOncology · NA · recruiting
NCT06614855 — A Phase IB 2 Dose Trial of IRS-1 HSV C134 (IND 17296) Administered Intratumorally in Patients With Recurrent Malignant G · Phase 1 · active not recruiting

Other CHA University trials

Trials by the same sponsor.

NCT07493668 — Fostrox Plus Lenvatinib vs Lenvatinib in Advanced Hepatocellular Carcinoma After First-line Immunotherapy · Phase 2 · not yet recruiting
NCT07151118 — ctDNA in Genetic Profiling and Clinical Outcomes of Advanced Biliary Tract Cancer · recruiting
NCT07142226 — Role of ctDNA in Genetic Profiling & Outcomes for Advanced BTC · recruiting
NCT07027891 — The Rule-Out Acute Myocardial Infarction Using Aritifical Intelligence Electrocardiogram (ROMIAE) 2 Trial · NA · recruiting
NCT07099807 — Carbohydrate Mouth Rinsing and Cognitive Response During Exercise · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07143812 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by CHA University
Last refreshed: 22 January 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07143812.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing